TransCode Therapeutics Inc (RNAZ) News

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR...

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical...

Form 8-K - Current report

TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics, Inc. Announces Results of Special Meeting PR Newswire BOSTON, Feb. 25, 2025 BOSTON, Feb. 25, 2025 /PRNewswire/...

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special...

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical...

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements PR...

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form PRE 14A - Other preliminary proxy statements

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary...